Preliminary program


Discover our sessions

 

Please note that this is a preliminary Program.

The final Program will differ in some details and will be available in May 2021. In particular, the content of the general sessions and “Focus on...” sessions will be defined on the basis of the abstract evaluation.

Clinical case discussions

These sessions offer participants an opportunity to discuss clinical cases that they encounter on a day-to-day basis in their work as lymphoma specialists but for which there might be no clearly defined best practices.

 

Titles and speakers to be announced.

Educational symposia

Two Educational symposia will take place in parallel on Wednesday morning before the official opening of the Conference. Each symposium will extensively address a specific topic, explained in 3 lectures (30 minutes each) by experts who will explore and scrutinize different aspects of the chosen topics.

 

High-risk follicular lymphoma
Lecture 1: Upfront identification: Carla Casulo, Rochester, NY (USA)
Lecture 2: Vulnerabilities in the tumor and microenvironment: Elias Campo, Barcelona (Spain)
Lecture 3: Treatment options: Brad Kahl, Saint Louis, MO (USA)

Immunotherapy
Lecture 1: CAR T-cell therapy optimization: Gilles Salles, New York, NY (USA)
Lecture 2: Allogeneic stem cell transplant in lymphomas: still an indication? Peter Dreger, Heidelberg (Germany)
Lecture 3: Bi-specific antibodies: Stephen Schuster, Philadelphia, PA (USA)

“Focus on…” sessions

These sessions are simultaneous sessions highlighting abstracts of scientific value that have not been selected for oral presentations during the general sessions. These sessions run in parallel and each session focuses on a particular topic. Each one-hour session consists of 6 presentations of 10 minutes each, including discussions and Q&A.

 

These sessions will be defined on the basis of abstract evaluation.

General sessions

Based on the abstracts received and accepted for oral presentations, general sessions will be devoted either to specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc) or to the presentation of laboratory and clinical research data grouped around a biologic topic (e.g. microenvironment, signaling pathway, surface antigens).

 

These sessions will be defined on the basis of the abstract evaluation.

Keynote lectures

The Keynotes lectures are among the most significant moments of the Congress and are dedicated to three prominent individuals engaged in the study of lymphomas, in the development of therapeutic strategies targeting lymphomas and in particular, those recognised for their important contributions throughout the history of the ICML. These lectures are assigned to distinguished scientists and researchers by the Organizing Committee, with the help of the Advisory Board, on the basis of various criteria.

 

“Henry Kaplan Memorial Lecture”

This celebrates the achievements of a lifetime career and acknowledges the activity that has led to significant and appreciated results over the years.
Henry Kaplan was a pioneer in the study and treatment of lymphomas and inspired the choice of Lugano as venue for the ICML.

“CLL”: Michael Hallek, Cologne (Germany)

Wednesday, June 16, Room A Palazzo dei Congressi

 

“Gianni Bonadonna Memorial Lecture”

This covers topics particularly important for translational research and marks our collaboration with the American Association for Cancer Research (AACR).
Gianni Bonadonna developed what has become the standard therapy for Hodgkin lymphoma (ABVD), which has maintained its importance for decades and he was one of the 3 oncologists who first decided to dedicate a congress entirely to malignant lymphomas.

“Liquid biopsy”: Ash A. Alizadeh, Stanford, CA (USA)

Thursday, June 17, Room A Palazzo dei Congressi

 

“John Ultmann Memorial Lecture”

This deals with clinical topics and is organized in collaboration with the European School of Oncology (ESO).

John Ultmann was a pioneer in the precise staging of Hodgkin's disease and its application as a guide for treatment. He was a member of the ICML Organizing Committee from its first edition until the year of his death in 2000.

“Immunosuppression and microenvironment”: Stephen M. Ansell, Rochester, MN (USA)

Friday, June 18, Room A Palazzo dei Congressi

“Meet the Professor” sessions

“Meet the Professor” sessions are 45-minutes lessons (30 minutes frontal lecture and 15 minutes discussion) that allow participants to meet internationally recognized experts and gain a deeper insight into topics of particular interest.

Out of 12 sessions, 8 are repeated twice and 4 are offered only once.

No registration is required but early arrival is recommended to ensure the possibility to enter the halls (participation is subject to availability of seats).

 

  • What's new in peripheral T-cell lymphoma therapy
    Stefano Luminari, Reggio Emilia (Italy)
  • Molecular classification of aggressive lymphomas
    Bjoern Chapuy, Göttingen (Germany)
  • Personalized medicine of Hodgkin lymphoma: mitigating toxicity while preserving cure
    Peter W.M. Johnson, Southampton (UK)
  • Recognizing and don't harming: borderlands of lymphoid malignancies
    Letitia Quintanilla-Martinez de Fend, Tübingen (Germany)
  • Sequencing of myeloma therapy: finding the right path among many standards
    S.Vincent Rajkumar, Rochester, MN (USA)
  • The molecular biology report explained to the clinician
    Richard Rosenquist Brandell, Stockholm (Sweden)
  • Cutaneous T-cell lymphoma
    Werner Kempf, Zürich (CH)
  • Histyocitosis
    Carl E. Allen, Houston, TX (USA)
  • New drugs and pharmacological interactions in real life
    Anastasios Stathis, Bellinzona (CH)
  • Use of available prognostic scores in treatment decision: beyond standard prognostic scores to include molecular/genetics/imaging
    John F. Seymour, Melbourne (Australia)
  • Mantle cell lymphoma
    Martin Dreyling, Munich (Germany)

The collection of articles written by speakers of the Educational symposia and Meet the Professor sessions represents the content of the Educational Book, published by John Wiley and Sons, Ltd. and distributed onsite to the attendees.

Special sessions

AACR-ICML joint session

The positive and fruitful collaboration between AACR and ICML, which started in 2015, continues and is particularly evident in this co-organized session.

This time, the role and potential of artificial intelligence in the study, diagnosis and treatment of lymphomas will be discussed.

 

Sessions devoted to Lymphoma Radiotherapy

Organised in collaboration with the International Lymphoma Radiation Oncology Group (ILROG), these workshops represent an opportunity for interaction and continuous learning not only for radiation oncologists, but also for medical oncologists and haematologists.

 

Special Forum of the IBSA Foundation for scientific research

As in 2017 and 2019, ICML participants will again have the possibility to attend a special edition of the IBSA Foundation Forum for scientific research The program will be defined in collaboration with the Foundation for Institute of Oncology Research (IOR).

   

5th International Workshop on Canine Lymphoma

This well-attended meeting fosters interdisciplinary contacts between researchers studying lymphoma in canine and other species. The 2021 edition will include an invited plenary lecture on a cutting-edge topic, an update on the activities of the European Canine Lymphoma Network, a round table on state of the art of canine multicentric lymphoma staging and a session for selected oral presentations.

“Take home messages” session

This is a lecture held at the closure of the Scientific Program that summarizes and highlights the themes addressed during the congress.

The participants will receive a series of hints and considerations that will facilitate the identification and understanding of the new knowledge presented and discussed in Lugano.


Speaker to be announced.